背景:在欧盟,大约有500万人受到精神病的影响,和大约30%-50%的精神分裂症患者有治疗抵抗精神分裂症(TRS)。移动健康(mHealth)干预措施可能有效预防复发,增加治疗依从性,控制精神分裂症的一些症状。精神分裂症患者似乎愿意并且能够使用智能手机来监测他们的症状并进行治疗干预。mHealth研究已与其他临床人群进行,但未在TRS人群中进行。
目的:本研究的目的是介绍m-RESIST干预3个月的前瞻性结果。本研究旨在评估可行性,可接受性,以及m-RESIST干预措施的可用性和使用该干预措施后TRS患者的满意度。
方法:对TRS患者进行无对照组的前瞻性多中心可行性研究。这项研究在3个地点进行:SantPau医院(巴塞罗那,西班牙),Semmelweis大学(布达佩斯,匈牙利),和Sheba医学中心和Gertner流行病学和健康政策研究所(Ramat-Gan,以色列)。m-RESIST干预包括智能手表,一个移动应用程序,一个基于网络的平台,和量身定制的治疗方案。将m-RESIST干预措施交付给患有TRS的患者,并由精神卫生保健提供者(精神科医生和心理学家)协助。可行性,可用性,可接受性,并测量了用户满意度。
结果:本研究对39例TRS患者进行。辍学率为18%(7/39),主要原因如下:后续损失,临床恶化,智能手表的身体不适,社会耻辱。患者对m-RESIST的接受度范围从中等到高。m-RESIST干预可以更好地控制疾病和适当的护理,一起提供用户友好和易于使用的技术。在用户体验方面,患者表示,m-RESIST能够更容易和更快地与临床医生沟通,并使他们感到更安全和受到保护.患者满意度总体良好:78%(25/32)认为服务质量良好或优秀,84%(27/32)报告说他们会再次使用它,94%(30/32)的人表示他们最满意。
结论:m-RESIST项目为基于新技术的新模块化方案提供了基础:m-RESIST干预。就可接受性而言,该计划被患者广泛接受,可用性,和满意度。我们的结果为TRS患者的mHealth技术提供了令人鼓舞的起点。
背景:ClinicalTrials.govNCT03064776;https://clinicaltrials.gov/ct2/show/record/NCT03064776。
■RR2-10.1136/bmjopen-2017-021346。
In the European Union, around 5 million people are affected by psychotic disorders, and approximately 30%-50% of people with schizophrenia have treatment-resistant schizophrenia (TRS). Mobile health (mHealth) interventions may be effective in preventing relapses, increasing treatment adherence, and managing some of the symptoms of schizophrenia. People with schizophrenia seem willing and able to use smartphones to monitor their symptoms and engage in therapeutic interventions. mHealth studies have been performed with other clinical populations but not in populations with TRS.
The purpose of this
study was to present the 3-month prospective results of the m-RESIST intervention. This
study aims to assess the feasibility, acceptability, and usability of the m-RESIST intervention and the satisfaction among patients with TRS after using this intervention.
A prospective multicenter feasibility
study without a control group was undertaken with patients with TRS. This
study was performed at 3 sites: Sant Pau Hospital (Barcelona, Spain), Semmelweis University (Budapest, Hungary), and Sheba Medical Center and Gertner Institute of Epidemiology and Health Policy Research (Ramat-Gan, Israel). The m-RESIST intervention consisted of a smartwatch, a mobile app, a web-based platform, and a tailored therapeutic program. The m-RESIST intervention was delivered to patients with TRS and assisted by mental health care providers (psychiatrists and psychologists). Feasibility, usability, acceptability, and user satisfaction were measured.
This
study was performed with 39 patients with TRS. The dropout rate was 18% (7/39), the main reasons being as follows: loss to follow-up, clinical worsening, physical discomfort of the smartwatch, and social stigma. Patients\' acceptance of m-RESIST ranged from moderate to high. The m-RESIST intervention could provide better control of the illness and appropriate care, together with offering user-friendly and easy-to-use technology. In terms of user experience, patients indicated that m-RESIST enabled easier and quicker communication with clinicians and made them feel more protected and safer. Patients\' satisfaction was generally good: 78% (25/32) considered the quality of service as good or excellent, 84% (27/32) reported that they would use it again, and 94% (30/32) reported that they were mostly satisfied.
The m-RESIST project has provided the basis for a new modular program based on novel technology: the m-RESIST intervention. This program was well-accepted by patients in terms of acceptability, usability, and satisfaction. Our results offer an encouraging starting point regarding mHealth technologies for patients with TRS.
ClinicalTrials.gov NCT03064776; https://clinicaltrials.gov/ct2/show/record/NCT03064776.
RR2-10.1136/bmjopen-2017-021346.